This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210922005141/en/
ICON receives multi-million Euro R&D support to accelerate decentralized clinical trial technology and data solutions. ICON executives welcomed the Tánaiste and Minister for Enterprise, Trade and Employment,
The COVID-19 pandemic has accelerated the clinical research industry’s move to hybrid and decentralised trials, requiring researchers and regulatory bodies to adapt to the ways participants live their connected and mobile lives. As the most advanced healthcare intelligence and clinical research organisation in the industry, ICON will utilise the funding to further invest in the build-out of its world-class technology and data solutions architecture. The support will promote broad clinical research participation while also delivering real-time access to data, higher levels of security, and improved timelines and reduced costs for customers.
The Tánaiste and Minister for Enterprise, Trade and Employment,
“I’m really happy Government is in a position to invest €4m in one of Ireland’s best known and respected life sciences companies. This funding will go into research and development in digital health technology and data analytics. The pandemic has brought into sharp focus the importance of both areas. With its roots in
The R&D support will help development of tech-enabled systems that provide greater flexibility and reduce the burden felt by clinical trial participants. In addition to visiting sites and meeting with trial investigators when needed, clinical trial participants should also have the choice to utilise virtual visits with their care teams, file eConsent forms, and report outcomes on mobile and wearable devices as part of their clinical trial experience. These options, combined with real-time data availability and analysis, improve participant retention, and reduce the timelines and costs for trial sponsors.
Plans are already in the works to invest in resources such as additional data sources, advanced analytical systems and digitisation, patient-focused mobile technology, and predictive tools that integrate artificial intelligence and machine learning.
“Clinical research has been evolving for many years, but the importance of expanding patient access to clinical research by decentralising many components through technology and data insights was never more apparent than in the last 18 months,” said
“ICON has an exceptional track record, delivering game changing clinical research solutions to the largest global biopharma and medical device companies in the world,” said
ICON is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in
Weber Shandwick (PR adviser)
Press & Media Relations
+353 86 021 0114